What are the recommended intervals for HPV self‑sampling (self‑collected vaginal swab) in average immunocompetent adults aged 25‑64, and how do the intervals differ for immunocompromised individuals or high‑risk men?

HPV Self-Swab Testing Intervals

For average-risk immunocompetent adults aged 25-65 using HPV self-collected vaginal swabs, repeat screening every 3 years after a negative result is recommended, which differs from the 5-year interval used for clinician-collected HPV testing. 1, 2

Screening Intervals by Collection Method

Self-Collected Vaginal Specimens (Average Risk, Ages 25-65)

• 3-year interval after negative HPV test 1, 2
• This shorter interval compared to clinician-collected samples reflects:
  • Limited long-term real-world effectiveness data
  • Slightly lower sensitivity for some HPV types (particularly HPV18 in at-home collection)
  • Most HPV-positive patients requiring additional follow-up steps 1

Clinician-Collected Cervical Specimens (Average Risk, Ages 25-65)

• 5-year interval after negative primary HPV test 3, 4
• This is the preferred screening strategy when available 3

Important Distinctions for High-Risk Populations

Immunocompromised Individuals

These recommendations do NOT apply to immunocompromised patients. 4, 5 For these populations:

• Annual screening is typically recommended 5
• Clinician-collected cervical specimens are strongly preferred over self-collection 1, 2
• Immunocompromised includes: HIV infection, organ transplantation, chemotherapy, chronic corticosteroid treatment 4

HIV-Positive Individuals (Specific Protocol)

• Test every 6 months during the first year, then annually thereafter 5
• Self-collection is not recommended for this population

High-Risk Men

The provided guidelines focus on cervical cancer screening in individuals with a cervix. HPV self-swab testing for anal cancer screening in high-risk men (particularly MSM with or without HIV) is not routinely recommended due to insufficient evidence 6. Digital anorectal examination may be considered for early cancer detection in these populations 6.

Critical Caveats for Self-Collection

Self-collection is acceptable but NOT preferred 1, 2:

• Clinician-collected cervical specimens remain the gold standard
• Self-collection should use only FDA-approved device/assay combinations 1
• Not appropriate for:
  • Surveillance after abnormal results
  • Post-colposcopy or post-treatment monitoring (clinician collection preferred) 2
  • Symptomatic individuals
  • Those with history of CIN2+ requiring extended surveillance 4

Special Surveillance Situations

After Treatment for High-Grade Precancer (CIN2/CIN3)

• Continue surveillance for at least 25 years after treatment, even beyond age 65 4, 6
• Initial testing at 6,18, and 30 months
• Long-term surveillance every 3 years with HPV/cotesting (or annually with cytology alone) 6
• Clinician-collected specimens strongly preferred for this surveillance 2

Screening Exit Criteria (Updated 2026)

To discontinue screening at age 65+, require:

• Negative HPV tests at ages 60 AND 65 years (preferred) 1
• If using self-collected specimens, must follow the 3-year interval, meaning testing would need to occur at appropriate intervals leading up to age 65 1

Common Pitfalls to Avoid

1. Do not extend self-collection intervals to 5 years – the evidence supports only 3-year intervals 1, 2
2. Do not use self-collection for immunocompromised patients – they require clinician collection and more frequent screening 1, 2
3. Do not use non-FDA-approved collection devices or assays – validation is device/assay-specific 1
4. Do not assume self-collection is equivalent for all HPV types – lower positive agreement seen for HPV18, particularly with at-home collection 7